Chrysos Locks in $200M Corporate Debt Facility to Scale PhotonAssay Rollout
Chrysos locks in $200M corporate debt facility to accelerate PhotonAssay™ global rollout
Chrysos Corporation (ASX: C79) has executed a new AUD $200 million three-year syndicated corporate debt facility, refinancing its existing asset-based financing structure. The facility is provided by a syndicate of three domestic financiers: Australia and New Zealand Banking Group Limited, National Australia Bank Limited, and Export Finance Australia. The shift to a corporate-style facility represents a meaningful step in the company’s financial maturity, designed to provide operational flexibility and support PhotonAssay™ manufacturing and deployment across multiple jurisdictions.
When big ASX news breaks, our subscribers know first
What the new facility delivers for Chrysos
The new corporate debt facilities improve on the existing arrangement across five key dimensions:
- More favourable debt pricing relative to the existing facility
- Lower commitment fee on undrawn facilities relative to the existing facility
- Improved covenants relative to the existing facility
- $105 million increase in funding headroom
- Existing asset-based financing to be extinguished upon drawdown
Facility structure at a glance
| Facility Size | Structure | Term | Lenders | Accordion Feature |
|---|---|---|---|---|
| AUD $200M | Term facility and revolving facility | 3 years | ANZ, NAB, Export Finance Australia | Allows additional commitments or facilities to be added, subject to agreed terms |
Security and guarantees are granted across subsidiaries in Australia, Canada, New Zealand, the United Kingdom, and the United States of America, with flexibility to add further jurisdictions.
Why corporate-style debt matters and what it means for investors
Asset-based lending ties a company’s borrowing capacity to the value of specific physical assets. In Chrysos’ case, that previously meant each individual PhotonAssay™ unit served as collateral underpinning the debt, which can limit how much a company can borrow and constrain its flexibility to fund growth independently of its asset base.
A corporate-style facility works differently. Rather than being anchored to individual asset values, it is extended based on the overall creditworthiness and cash-generating capacity of the business as a whole. This gives Chrysos greater freedom to fund manufacturing, deployment, and international expansion without being restricted by the value of any single unit.
For investors, the transition carries a clear signal. Tier-one domestic lenders extending $200 million on corporate terms reflects confidence in Chrysos’ contracted revenue base and the quality of its long-term customer relationships. It positions the company to scale operations in a way that asset-based financing structures are not designed to support.
CEO commentary
Dirk Treasure, Managing Director and CEO
“We are pleased to have this facility in place to support the Company’s continued growth and accelerating deployment cadence. Continued adoption of PhotonAssay™ is driving strong demand across multiple regions, reflected in the additional four contracts signed with laboratories since our last update. The facility provides Chrysos with the flexibility and capital support required to scale deployments, expand our global footprint and maintain momentum as customer adoption continues to strengthen.”
The next major ASX story will hit our subscribers first
Growth pipeline and commercial momentum backing the facility
The facility arrives at a point of building operational momentum, with the capital required to sustain and accelerate it. The forward order book and manufacturing target together illustrate why access to $200 million in flexible funding is material:
- Target manufacturing cadence: The facility supports Chrysos’ return to 18 units per year.
- Forward order book: 22 PhotonAssay™ units plus 27 long-lead components currently on order.
- New lease agreements year-to-date: 23 signed in total, including four signed since the company’s last update.
- Notable new contracts: SGS (expanding global footprint) and ALS (a second unit for Saudi Arabia).
- Processing milestone: May 2026 marked the third consecutive month of processing more than one million samples, supported by high fleet utilisation across the PhotonAssay™ network.
- Active deployments: Two units currently being deployed across two regions.
A buoyant gold market has supported high fleet utilisation and reinforced demand across the PhotonAssay™ customer base, consistent with the announcement’s characterisation of conditions. With the order book extending well into FY27, the new facility provides the financial platform to convert that pipeline into deployed units at pace.
Stay Ahead on ASX Tech and Industrials News
Big News Blast delivers FREE breaking ASX announcements to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers who never miss a market-moving update. Click the “Free Alerts” button at StockWire X to get started today.